|[May 08, 2014]
Research and Markets: TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update 2014
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/cm2s97/tnfalpha)
has announced the addition of the "TNF-Alpha
Signaling Pathway in Oncology Drug Pipeline Update 2014" report
to their offering.
The TNF-alpha signaling pathway stimulates the MAPK signaling module and
There are today 359 companies plus partners developing 531 TNF-alpha
pathway targeting drugs in 1960 developmental projects in cancer. In
addition, there are 7 suspended drugs and the accumulated number of
ceased drugs over the last years amount to another 250 drugs.
TNF-Alpha Signaling Pathway In Oncology Drug Pipeline Update lists all
drugs and gives you a progress analysis on each one of them. Identified
drugs are linked to 247 different targets. All included targets have
been ross-referenced for the presence of mutations associated with
human cancer. To date 243 out of the 245 studied drug targets so far
have been recorded with somatic mutations.
The software application lets you narrow in on these mutations and links
out to the mutational analysis for each of the drug targets for detailed
information. All drugs targets are further categorized on in the
software application by 54 classifications of molecular function and
with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Drug Pipeline Update at a Glance
Includes more than 359 principal companies plus their collaborators.
There is direct access from inside the application to web pages of all
Drug name & Synonyms
Lists commercial, generic and code names for drugs.
This Drug Pipeline Update contains 531 TNF-alpha pathway targeting
drugs in development, which have a total of 1960 developmental
projects in cancer. In addition there are suspended and ceased drugs.
Included TNF-alpha pathway targeting drugs are also in development for
224 other indications, where of 140 are different cancer indications.
Pipeline Breakdown According to Number of Drugs
Marketed # 39
Registered # 1
Pre-registration # 6
Phase III # 64
Phase II # 184
Phase I # 234
Preclinical # 280
No Data # 4
Suspended # 7
Ceased # 250
For more information visit http://www.researchandmarkets.com/research/cm2s97/tnfalpha.
[ Back To Technology News's Homepage ]